Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Biotechwantabe who wrote (3137)	11/4/2020 11:53:24 PM
From: Biotechwantabe	Respond to of 3557

The dilemma: Works best administered early. Works best on seronegative. For outpatient it’s difficult/expensive to determine seronegative. Without a rapid test you end up administering to all outpatient. Therefore the value of the product is reduced. And you don’t have sufficient supply to suppress spread. If you had sufficient supply, you could reduce hospital visits, saving system from possible overload. With hospitalized patients you provide more value per dose. As long as you administer early enough. Assuming they can determine an effective window. Reduce hospital visit duration and save lives. So, do you wait for hospitalized clinical trail results before using limited supply or waste it on outpatients. Prophylactic seems really wasteful without sufficient quality, low cost, and sq. Probably when seronegative and vaccines ineffective. Disclaimer- I know nothing.